New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 4, 2014, Pages 364-368

  Shrum, Kara J P ^a   Gill, Sarah E ^a   Thompson, Laura K ^b   Blackhurst, Dawn W ^a   Puls, Larry E ^c  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

^b FURMAN UNIVERSITY   (United States)

^c Cancer Centers of the Carolinas   (United States)

Author keywords

Cancer; Chemotherapy; Complications; Gemcitabine; Heart failure; Ovary

Indexed keywords

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CORONARY ARTERY DISEASE; DEOXYCYTIDINE; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84905083828     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31827b459a     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts and Figures 2012. Available at: http://www.cancer.org/Research/CancerFacts Figures/CancerFactsFigures/cancer- facts-figures-2012 Accessed May 24, 2012.
2. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita Vt Jr, Hellman S, Rosenburg RA, eds. Cancer: Principles & Practice of Oncology. 6th ed.. Philadelphia (PA): Lippincott Williams & Wilkins; 2001: 1597-1632.
3. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol. 2005; 3: 723-735.
4. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol. 1999; 18: 356a, [abstract].
5. Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002; 2(suppl 1): S22-S30.
6. Cohn DE, Valmadre S, Resnick KE, et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gyn Oncol. 2006; 102: 134-139.
7. Jurado Garcia JM, Sanchez A, Pajares B, et al. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clinical and Translational Oncology. 2008; 10: 583-586.
8. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
9. Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997; 15: 2183-2193.
10. Homesley HD, Morris R, Munkarah A. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001; 83: 394-399.
11. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly singleagent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002; 20: 2365-2369.
12. Havrilesky LJ, Tait DL, Sayer RA, et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol. 2003; 80: 51-57.
13. Markman M. Viewing ovarian cancer as a chronic disease: what exactly does this mean? Editorial. Gynecol Oncol. 2006; 100: 229-230.
14. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinumsensitive recurrent ovarian cancer: an intergroup trial of the AGOOVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24: 4699-4707.
15. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Bynecol Oncol. 1996; 63: 89-93.
16. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Sem Oncol. 1996; 23(suppl 10): 72-76.
17. Watanabe Y, Koike E, Nakai H, et al. Phase II study of singleagent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer. Int J Clin Oncol. 2008; 4: 345-348.
18. Ojeda GB, Gonzalez MA, Bover BI, et al. A phase II trial of fixeddose rate gemcitabine in platinum-resistant ovarian cancer: a GEICO Trial. Am J Clin Oncol. 2008; 31: 481-487.
19. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
20. Eli Lilly and Company. Gemcitabine and incidence of congestive heart failure. Post marketing data. Data from December 1995-May 15, 2006.
21. Buja LM, Ferrans VJ, Mayers RJ, et al. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973; 32: 771-778.
22. Tong J, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol. 1991; 260: H909-H916.
23. Gosalvez M, van Rossum GDV, Blanco MF. Inhibition of sodium potassium activated adenosine 5'-triphosphatase and ion transport by adriamycin. Cancer Res. 1979; 39: 257-261.
24. Singal PK, Segstro RJ, Singh RP, et al. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol. 1985; 1: 139-147.
25. Singal PK, Pierce GN. Adriamycin stimulated low-affinity Ca2+ binding and lipid peroxidation but depressed myocardial function. Am J Physiol. 1986; 250: H419-H425.
26. Singal PK, Panagia V. Direct effect of adriamycin on the rat heart sarcolemma. Res Comm Chem Pathol Pharmacol. 1984; 43: 67-77.
27. Olson HM, Young DM, Prieur DJ, et al. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 1974; 77: 439-454.
28. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987; 19: 817-828.
29. Revis NW, Marusic N. Glutathione peroxidase activity and selenium concentration in the hearts of doxorubicin-treated rabbits. J Mol Cell Cardiol. 1978; 10: 945-951.
30. Doroshow JH, Locher GY, Baldinger J, et al. The effect of doxorubicin on hepatic and cardiac glutathione. Res Commu Chem Pathol Pharmacol. 1979; 26: 285-295.
31. Zhang J, Clark JR Jr, Herman EH, et al. Doxorubicin induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol. 1996; 28: 1931-1943.
32. GEMZAR (gemcitabine HCl for injection) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2006.
33. Aapro MS, Martin C, Hatty S. Gemcitabine- a safety review. Anticancer Drugs. 1998; 9: 191-201.
34. Shaib W, Lansigan F, Cornfeld D, et al. Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP. 2008; 9: 708-714.
35. Ko E, Lee S, Goodman A. Gemcitabine pulmonary toxicity in ovarian cancer. Oncologist. 2008; 13: 807-811.
36. Gridelli C, Cigolari S, Gallo C, et al. MILES Investigators. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001; 31: 277-284.
37. Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol. 1999; 17: 3596-3602.
38. Voortman G, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006; 6: 129.
39. Yajima T, Furukawa Y, Ishii Y, et al. Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years. Gan To Kagaku Ryoho. 2004; 31: 953-957.
40. Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, et al. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol. 2009; 161: 660-663.
41. Glezerman I, Kris MG, Miller V, et al. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol. 2009; 71: 130-139.
42. Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006; 7: 51-58.